Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of β-catenin-dependent signaling

Neoplasia

Volumn 12, Issue 5, 2010, Pages 415-424

  Kaur, Manjinder ^a   Velmurugan, Balaiya ^a   Tyagi, Alpna ^a   Agarwal, Chapla ^a,b   Singh, Rana P ^a,c   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIN C; CYCLIN D1; CYCLIN DEPENDENT KINASE 8; CYCLINE; MYC PROTEIN; SILIBININ; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

EID: 77951679964     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10188     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
2. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, and Schuman LM (2000). The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343, 1603-1607.
3. Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, Wingo PA, Howe HL, Ries LA, Miller BA, et al. (2007). Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 110, 2119-2152.
4. Wilkins T and Reynolds PL (2008). Colorectal cancer: a summary of the evidence for screening and prevention. Am Fam Physician 78, 1385-1392.
5. Half E and Arber N (2009). Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 10, 211-219.
6. Corrêa Lima MP and Gomes-da-Silva MH (2005). Colorectal cancer: lifestyle and dietary factors. Nutr Hosp 20, 235-241.
7. Coyle YM (2009). Lifestyle, genes, and cancer. Methods Mol Biol 472, 25-56.
8. Nomura AM, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Pike MC, and Kolonel LN (2008). Association of vegetable, fruit, and grain intakes with colorectal cancer: the Multiethnic Cohort Study. Am J Clin Nutr 88, 730-737.
9. Van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, Casagrande C, Tjønneland A, Olsen A, Overvad K, et al. (2009). Fruit, vegetables, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 89, 1441-1452.
10. Millen AF, Subar AF, Graubard BI, Peters U, Hayes RB, Weissfeld JL, Yokochi LA, Ziegler RG, and PLCO Cancer Screening Trial Project Team (2007). Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr 86, 1754-1764.
11. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, and Berry DP (2009). Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 18, 13-25.
12. Khor TO, Yu S, and Kong AN (2008). Dietary cancer chemopreventive agents-targeting inflammation and Nrf2 signaling pathway. Planta Med 74, 1540-1547.
13. Surh YJ (2003). Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780.
14. Kaur M, Singh RP, Gu M, Agarwal R, and Agarwal C (2006). Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells. Clin Cancer Res 12, 6194-6202.
15. Velmurugan B, Singh RP, Tyagi A, and Agarwal R (2008). Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila Pa) 1, 376-384.
16. Singh RP, Gu M, and Agarwal R (2008). Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 68, 2043-2050.
17. Singh RP and Agarwal R (2006). Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45, 436-442.
18. Singh RPand Agarwal R (2005). Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41, 1969-1979.
19. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, and Agarwal R (2003). Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 22, 8271-8282.
20. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, and Agarwal R (2007). Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 6, 3248-3255.
21. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, et al. (2007). Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67, 11083-11091.
22. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, and Agarwal R (2006). Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 98, 846-855.
23. Moon RT, Kohn AD, De Ferrari GV, and Kaykas A (2004). WNTand β-catenin signalling: diseases and therapies. Nat Rev Genet 5, 691-701.
24. Gottardi CJ and Gumbiner BM (2001). Adhesion signaling: how β-catenin interacts with its partners. Curr Biol 11, R792-R794.
25. Barker NV (2008). The canonical Wnt/β-catenin signalling pathway. Methods Mol Biol 468, 5-15.
26. Takemaru KI, Ohmitsu M, and Li FQ (2008). An oncogenic hub: β-catenin as a molecular target for cancer therapeutics. Handb Exp Pharmacol 186, 261-284.
27. Fodde R (2002). The APC gene in colorectal cancer. Eur J Cancer 38, 867-871.
28. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, and Bodmer WF (1997). β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94, 10330-10334.
29. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, and Kinzler KW (1997). Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790.
30. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, and Tomlinson IP (2000). APC mutations in sporadic colorectal tumors: a mutational hotspot and interdependence of the two hits. Proc Natl Acad Sci USA 97, 3352-3357.
31. Dhanalakshmi S, Singh RP, Agarwal C, and Agarwal R (2002). Silibinin inhibits constitutiveand TNFα-induced activationofNF-κBand sensitizes human prostate carcinoma DU145 cells to TNFα-induced apoptosis. Oncogene 21, 1759-1767.
32. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, et al. (2008). CDK8 is a colorectalcanceroncogene that regulates β-catenin activity. Nature 455, 547-551.
33. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, and Kroll DJ (2005). Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on anti-proliferative end points in human prostate carcinoma cells. Cancer Res 65, 4448-4457.
34. Luper S (1998). A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 3, 410-421.
35. Schneikert J and Behrens J (2007). The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 56, 417-425.
36. Kimelman D and Xu W (2006). β-Catenin destruction complex: insights and questions from a structural perspective. Oncogene 25, 7482-7491.
37. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, and Matsunami N (2001). Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 7, 927-936.
38. Dillard AC and Lane MA (2007). Retinol decreases β-catenin protein levels in retinoic acid-resistant colon cancer cell lines. Mol Carcinog 46, 315-329.
39. Nagase H and Nakamura Y (1993). Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 2, 425-434.
40. Moon RT and Miller JR (1997). The APC tumor suppressor protein in development and cancer. Trends Genet 13, 256-258.
41. Conaway RC, Sato S, Tomomori-Sato C, Yao T, and Conaway JW (2005). The mammalian Mediator complex and its role in transcriptional regulation. Trends Biochem Sci 30, 250-255.
42. Morris EJ, Ji JY, Yang F, Di Stefano L, Herr A, Moon NS, Kwon EJ, Haigis KM, Näär AM, and Dyson NJ (2008). E2F1 represses β-catenin transcription and is antagonized by both pRB and CDK8. Nature 455, 552-556.
43. Behrens J (2000). Control of β-catenin signaling in tumor development. Ann N Y Acad Sci 910, 21-33.
44. Fu M, Wang C, Li Z, Sakamaki T, and Pestell RG (2004). Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145, 5439-5447.
45. Nasi S, Ciarapica R, Jucker R, Rosati J, and Soucek L (2001). Making decisions through Myc. FEBS Lett 490, 153-162.
46. Wilkins JA and Sansom OJ (2008). C-Myc is a critical mediator of the phenotypes of APC loss in the intestine. Cancer Res 68, 4963-4966.
47. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, and Clarke AR (2007). Myc deletion rescues APC deficiency in the small intestine. Nature 446, 676-679.
48. Reagan-Shaw S, Nihal M, and Ahmad N (2008). Dose translation from animal to human studies revisited. FASEB J 22, 659-661.
49. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, et al. (2006). Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 12, 2944-2950.